Sionna Therapeutics Raises $111M in Series B Financing

Sionna Therapeutics

Sionna Therapeutics, a Boston, MA-based life sciences company developing differentiated treatments for cystic fibrosis (CF), closed a $111m Series B financing.

The round was led by OrbiMed with participation from funds advised by T. Rowe Price Associates, Inc., Q Healthcare Holdings, LLC., a wholly-owned subsidiary of QIA, the sovereign wealth fund of Qatar, and previous investors including RA Capital, TPG’s The Rise Fund, Atlas Venture, and the Cystic Fibrosis Foundation.

The company, which has raised approximately $150m to date, intends to use the funds to advance the development of a franchise of small molecules targeting NBD1 and complementary modulators, including NBD1’s interface with the intracellular loop 4 (ICL4) region and the transmembrane domain 1 (TMD1) of CFTR. Sionna will submit Investigational New Drug Applications (IND) within the next 12 month for its first NBD1-targeted program, SION-638, as well for its ICL4 lead program, SION-99.

Mike Cloonan, President & Chief Executive Officer, Charlotte McKee (M.D.), Chief Medical Officer John Macor (Ph.D.), Chief Scientific Officer Elena Ridloff, Chief Finance Officer, Greg Hurlbut (Ph.D.), Co-founder Senior Vice President Discovery Research and Mark Munson (Ph.D.), Co-founders, Vice President Medicinal Chemistry. Sionna Therapeutics is a life-science company that focuses on developing differentiated and highly effective treatments for cystic CFTR. This protein is associated with disease progression. The company is advancing a pipeline of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that is defective in CF, by stabilizing CFTR’s first nucleotide-binding domain (NBD1).

The company’s Board of Directors includes:

  • Josh Resnick, M.D., Chair, Managing Director, RA Capital
  • Bruce Booth, D.Phil., Partner, Atlas Venture
  • Mike Cloonan, President & CEO, Sionna Therapeutics
  • Lucian Iancovici, M.D., Managing Director, TPG Life Sciences Innovation
  • Adam Rosenberg, J.D., Venture Partner, RA Capital
  • Peter Thompson M.D., Partner at OrbiMed
Get latest news from African Startup ecosystem

Latest stories

You might also like...